Elevated Homocysteine and Asymmetric Dimethyl Arginine Levels in Pulmonary Hypertension Associated With Congenital Heart Disease

Basit Öğe Kaydı
dc.contributor.authorSanli, Cihat
dc.contributor.authorOguz, Deniz
dc.contributor.authorOlgunturk, Rana
dc.contributor.authorTunaoglu, Fatma Sedef
dc.contributor.authorKula, Serdar
dc.contributor.authorPasaoglu, Hatice
dc.contributor.authorCevik, Ayhan
dc.date.accessioned2020-06-25T17:52:25Z
dc.date.available2020-06-25T17:52:25Z
dc.date.issued2012
dc.departmentKırıkkale Üniversitesi
dc.description.abstractPulmonary arterial hypertension (PAH) is a major cause of morbidity and mortality among patients with congenital heart disease (CHD). This study was designed to determine biomarker levels in patients with PAH associated with CHD (PAH-CHD) and CHD patients without PAH and to investigate the relationship of these potential biomarkers with hemodynamic findings. In this prospective single-center study, patients with CHD were analyzed according to the presence or absence of PAH and compared with healthy control subjects. Cardiac catheterization and echocardiographs were performed. Plasma homocysteine, asymmetric dimethyl arginine (ADMA), and nitric oxide (NO) levels were determined by enzyme-linked immunosorbent assay. Homocysteine and ADMA levels were higher in the PAH-CHD group (n = 30) than among CHD patients with left-to-right shunting but no PAH (n = 20; P < 0.001) and healthy control subjects (n = 20; P < 0.001). There was no difference in NO levels. Cyanotic PAH-CHD patients had significantly higher homocysteine than acyanotic patients in the same group. No correlation was shown between echocardiographic/hemodynamic parameters and homocysteine, ADMA, and NO levels. Homocysteine and ADMA levels are increased in patients with PAH-CHD. These parameters have the potential to be used as biomarkers in the diagnosis and follow-up evaluation of patients with PAH-CHD. However, large, multicentered prospective studies are required to facilitate routine use of these biologic markers in the clinical setting.en_US
dc.description.sponsorshipActelion Pharmaceuticals Ltd.en_US
dc.description.sponsorshipThe authors thank Elements Communications for medical writing assistance during the preparation of this manuscript, funded by Actelion Pharmaceuticals Ltd.en_US
dc.identifier.citationclosedAccessen_US
dc.identifier.doi10.1007/s00246-012-0321-9
dc.identifier.endpage1331en_US
dc.identifier.issn0172-0643
dc.identifier.issn1432-1971
dc.identifier.issue8en_US
dc.identifier.pmid22526220
dc.identifier.scopus2-s2.0-84878261080
dc.identifier.scopusqualityQ2
dc.identifier.startpage1323en_US
dc.identifier.urihttps://doi.org/10.1007/s00246-012-0321-9
dc.identifier.urihttps://hdl.handle.net/20.500.12587/5153
dc.identifier.volume33en_US
dc.identifier.wosWOS:000311792000013
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringeren_US
dc.relation.ispartofPediatric Cardiology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectADMAen_US
dc.subjectHomocysteineen_US
dc.subjectNOen_US
dc.subjectPulmonary arterial hypertensionen_US
dc.titleElevated Homocysteine and Asymmetric Dimethyl Arginine Levels in Pulmonary Hypertension Associated With Congenital Heart Diseaseen_US
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
Elevated Homocysteine and Asymmetric Dimethyl Arginine Levels in Pulmonary Hypertension Associated With Congenital Heart Disease.pdf
Boyut:
283.41 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text
İndir

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu